Alexandria Real Estate Equities Faces Class Action Over $323.9M Impairment Charge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Class Action Notice: The Portnoy Law Firm advises Alexandria Real Estate Equities investors of a class action for those who purchased securities between January 27 and October 27, 2025, with a deadline of January 26, 2026, to file a lead plaintiff motion to protect their legal rights.
- Declining Financial Performance: Alexandria reported disappointing third-quarter results for 2025, including a $323.9 million impairment charge, primarily $206 million related to its Long Island City property, leading to a downward revision of its full-year funds from operations (FFO) guidance, which negatively impacted investor confidence.
- Stock Price Volatility: Following the financial warning, Alexandria's stock price plummeted by $14.93, or 19.17%, closing at $62.94 on October 28, 2025, reflecting market concerns about the company's future performance and investor panic.
- Legal Support and Compensation: The Portnoy Law Firm offers complimentary case evaluations for affected investors and has previously recovered over $5.5 billion for aggrieved investors, demonstrating its expertise and success rate in handling similar cases.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 64.78 USD with a low forecast of 30.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
9 Hold
1 Sell
Hold
Current: 54.360
Low
30.00
Averages
64.78
High
104.00
Current: 54.360
Low
30.00
Averages
64.78
High
104.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
